U.S. Markets closed

Coronado Biosciences reports Phase 1 clinical trial results for TSO in Crohn's

Coronado Biosciences announced positive results from the Phase 1 clinical trial of TSO, or Trichuris suis ova or CNDO-201, in patients with Crohn's disease. The study showed that TSO is safe and well tolerated. TSO, the microscopic eggs of the pig whipworm, is a novel, orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines. Dr. Bobby W. Sandage, Jr., President and CEO commented: "We are on track to initiate our Phase 2 dose ranging study in the second quarter of this year."